ILR-DM123-100μg / 询价
ILR-DM123-500μg / 询价
ILR-DM123-500μgx2 / 询价
Canine IL-23R Protein
Recombinant Canine IL-23R Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Gly24-Asp354 [Accession | A0A8I3PXL0].
The protein has a predicted MW of 39.31 kDa. Due to glycosylation, the protein migrates to 55-70 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Canine IL-23R on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Canine IL-23R is greater than 95% as determined by SEC-HPLC.
Immobilized Canine IL-23R, His Tag at 5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Human IL-23 alpha&IL-12 beta, His Tag with the EC50 of 2.7μg/ml determined by ELISA.
Interleukin 23 (IL-23) is a heterodimeric cytokine composed of two disulfide-linked subunits, a p19 subunit that is unique to IL-23, and a p40 subunit that is shared with IL-12. The functional IL-23 receptor complex consists of two receptor subunits, the IL-12 receptor beta 1 subunit (IL-12 R beta 1) and the IL-23-specific receptor subunit (IL-23 R).This receptor associates with IL12RB1 to form the interleukin-23 receptor. Binds IL23 and mediates T-cells, NK cells and possibly certain macrophage/myeloid cells stimulation probably through activation of the Jak-Stat signaling cascade.
IBD17; IL-23 R; IL-23 receptor
(1)Campa M , Mansouri B , Warren R , et al. A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis[J]. Dermatology and Therapy, 2016, 6(1):1-12.
